Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Repligen Cp (RGEN)

Repligen Cp (RGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,811,964
  • Shares Outstanding, K 51,531
  • Annual Sales, $ 194,030 K
  • Annual Income, $ 16,620 K
  • 60-Month Beta 1.08
  • Price/Sales 24.47
  • Price/Cash Flow 82.30
  • Price/Book 5.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.20
  • Number of Estimates 5
  • High Estimate 0.22
  • Low Estimate 0.18
  • Prior Year 0.20
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
85.67 +8.16%
on 08/05/19
99.25 -6.64%
on 08/01/19
+4.38 (+4.96%)
since 07/22/19
3-Month
66.21 +39.95%
on 05/23/19
99.25 -6.64%
on 08/01/19
+24.14 (+35.23%)
since 05/22/19
52-Week
48.26 +92.00%
on 12/24/18
99.25 -6.64%
on 08/01/19
+41.05 (+79.54%)
since 08/22/18

Most Recent Stories

More News
Uptrend Call Working As Repligen Corp Stock Rises 46.4% (RGEN)

SmarTrend identified an Uptrend for Repligen Corp (NASDAQ:RGEN) on April 26th, 2019 at $63.80. In approximately 4 months, Repligen Corp has returned 46.38% as of today's recent price of $93.38.

RGEN : 92.66 (-0.77%)
Repligen Corp Shares Up 39.3% Since SmarTrend's Buy Recommendation (RGEN)

SmarTrend identified an Uptrend for Repligen Corp (NASDAQ:RGEN) on April 26th, 2019 at $63.80. In approximately 4 months, Repligen Corp has returned 39.31% as of today's recent price of $88.87.

RGEN : 92.66 (-0.77%)
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

Sector ETF report for PSCH

XLV : 90.86 (-0.49%)
VHT : 170.44 (-0.59%)
LHCG : 120.25 (+0.37%)
RGEN : 92.66 (-0.77%)
NEOG : 71.79 (-0.53%)
PSCH : 115.52 (-0.97%)
Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark

Blueprint Medicines (BPMC) suffers wider-than-expected loss in the second quarter while sales beat estimates.

RGEN : 92.66 (-0.77%)
ACOR : 3.18 (+1.27%)
BPMC : 77.27 (-2.79%)
RHHBY : 34.5600 (-0.63%)
Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.

MYL : 19.04 (-0.26%)
MRUS : 18.00 (unch)
RGEN : 92.66 (-0.77%)
ACOR : 3.18 (+1.27%)
Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales

Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.

AGIO : 41.84 (-3.73%)
CELG : 95.71 (+0.03%)
RGEN : 92.66 (-0.77%)
ACOR : 3.18 (+1.27%)
Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View

Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.

CRSP : 48.86 (-0.24%)
RGEN : 92.66 (-0.77%)
VRTX : 184.24 (-1.16%)
ACOR : 3.18 (+1.27%)
Repligen: 2Q Earnings Snapshot

WALTHAM, Mass. (AP) _ Repligen Corp. (RGEN) on Thursday reported second-quarter net income of $8.1 million.

RGEN : 92.66 (-0.77%)
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance

-- Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth

RGEN : 92.66 (-0.77%)
Powell Gives Space for Growth, Market Overreacts: 5 Picks

Although market participants were expecting a quarter percentage point of cut, they were taken aback by Fed Chair Jerome Powell's comment that this rate cut is "in the nature of a mid-cycle adjustment...

TDY : 307.82 (+0.71%)
RGEN : 92.66 (-0.77%)
CHGG : 40.86 (-0.27%)
DAL : 57.96 (-0.09%)
SAM : 437.44 (-0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade RGEN with:

Business Summary

Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide....

See More

Key Turning Points

2nd Resistance Point 95.40
1st Resistance Point 94.03
Last Price 92.66
1st Support Level 90.86
2nd Support Level 89.06

See More

52-Week High 99.25
Last Price 92.66
Fibonacci 61.8% 79.77
Fibonacci 50% 73.75
Fibonacci 38.2% 67.74
52-Week Low 48.26

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar